Pharmacological activation of Rap1 antagonizes the endothelial barrier disruption induced by exotoxins ExoS and ExoT of Pseudomonas aeruginosa

Infection and Immunity

Volumn 83, Issue 5, 2015, Pages 1820-1829

  Bouillot, Stéphanie ^a,b,c,d   Attrée, Ina ^a,b,c,d   Huber, Philippe ^a,b,c,d  

^a UNIV GRENOBLE ALPES   (France)

^b CNRS   (France)

^c CEA GRENOBLE   (France)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; EXOTOXIN EXOS; EXOTOXIN EXOT; EXOTOXIN EXOU; FORSKOLIN; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PROTEIN KINASE B; PSEUDOMONAS EXOTOXIN; RAP1 PROTEIN; ROLIPRAM; SALMETEROL; UNCLASSIFIED DRUG; BACTERIAL TOXIN; ENZYME ACTIVATOR; EXOENZYME S; EXOT PROTEIN, PSEUDOMONAS AERUGINOSA; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TELOMERE BINDING PROTEIN; TERF2IP PROTEIN, HUMAN;

ACTIN FILAMENT; ADENOSINE DIPHOSPHATE RIBOSYLATION; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CELL ADHESION; CELL JUNCTION; CELL MIGRATION; CELL TRANSMIGRATION; CFU COUNTING; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENZYME PHOSPHORYLATION; FLUORESCENCE MICROSCOPY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HOST CELL; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; TYPE III SECRETION SYSTEM; UMBILICAL VEIN ENDOTHELIAL CELL; WILD TYPE; ANTAGONISTS AND INHIBITORS; CELL CULTURE; DRUG EFFECTS; ENDOTHELIUM CELL; METABOLISM; MICROBIOLOGY; PHYSIOLOGY;

ADP RIBOSE TRANSFERASES; BACTERIAL TOXINS; CELLS, CULTURED; COLFORSIN; ENDOTHELIAL CELLS; ENZYME ACTIVATORS; GTPASE-ACTIVATING PROTEINS; HUMANS; PSEUDOMONAS AERUGINOSA; TELOMERE-BINDING PROTEINS;

EID: 84928175377     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00010-15     Document Type: Article

References (45)

1. Lee WL, Slutsky AS. 2010. Sepsis and endothelial permeability. N Engl J Med 363:689-691. http://dx.doi.org/10.1056/NEJMcibr1007320.
2. Boucher HW, Talbot GH, Benjamin DK, Jr, Bradley J, Guidos RJ, Jones RN, Murray BE, Bonomo RA, Gilbert D, Infectious Diseases Society of America. 2013. 10×'20 progress: development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 56:1685-1694. http://dx.doi.org/10.1093/cid/cit152.
3. Peterson LR. 2009. Bad bugs, no drugs: no ESCAPE revisited. Clin Infect Dis 49:992-993. http://dx.doi.org/10.1086/605539.
4. Filloux A. 2011. Protein secretion systems in Pseudomonas aeruginosa: an essay on diversity, evolution, and function. Front Microbiol 2:155. http://dx.doi.org/10.3389/fmicb.2011.00155.
5. El-Solh AA, Hattemer A, Hauser AR, Alhajhusain A, Vora H. 2012. Clinical outcomes of type III Pseudomonas aeruginosa bacteremia. Crit Care Med 40:1157-1163. http://dx.doi.org/10.1097/CCM.0b013e3182377906.
6. Hauser AR, Cobb E, Bodi M, Mariscal D, Valles J, Engel JN, Rello J. 2002. Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit Care Med 30:521-528. http://dx.doi.org/10.1097/00003246-200203000-00005.
7. Le Berre R, Nguyen S, Nowak E, Kipnis E, Pierre M, Quenee L, Ader F, Lancel S, Courcol R, Guery BP, Faure K, Pyopneumagen G. 2011. Relative contribution of three main virulence factors in Pseudomonas aeruginosa pneumonia. Crit Care Med 39:2113-2120. http://dx.doi.org/10.1097/CCM.0b013e31821e899f.
8. Vance RE, Rietsch A, Mekalanos JJ. 2005. Role of the type III secreted exoenzymes S, T, and Y in systemic spread of Pseudomonas aeruginosa PAO1 in vivo. Infect Immun 73:1706-1713. http://dx.doi.org/10.1128/IAI.73.3.1706-1713.2005.
9. Galle M, Carpentier I, Beyaert R. 2012. Structure and function of the type III secretion system of Pseudomonas aeruginosa. Curr Protein Peptide Sci 13:831-842. http://dx.doi.org/10.2174/138920312804871210.
10. Hauser AR. 2009. The type III secretion system of Pseudomonas aeruginosa: infection by injection. Nat Rev Microbiol 7:654-665. http://dx.doi.org/10.1038/nrmicro2199.
11. Izore T, Perdu C, Job V, Attree I, Faudry E, Dessen A. 2011. Structural characterization and membrane localization of ExsB from the type III secretion system (T3SS) of Pseudomonas aeruginosa. J Mol Biol 413:236-246. http://dx.doi.org/10.1016/j.jmb.2011.07.043.
12. Berthelot P, Attree I, Plesiat P, Chabert J, de Bentzmann S, Pozzetto B, Grattard F, Groupe d'Etudes des Septicemies Pseudomonas. 2003. Genotypic and phenotypic analysis of type III secretion system in a cohort of Pseudomonas aeruginosa bacteremia isolates: evidence for a possible association betweenOserotypes and exo genes. J Infect Dis 188:512-518. http://dx.doi.org/10.1086/377000.
13. Frank DW. 2012. Research topic on Pseudomonas aeruginosa, biology, genetics, and host-pathogen interactions. Front Microbiol 3:20. http://dx.doi.org/10.3389/fmicb.2012.00020.
14. Gendrin C, Contreras-Martel C, Bouillot S, Elsen S, Lemaire D, Skoufias DA, Huber P, Attree I, Dessen A. 2012. Structural basis of cytotoxicity mediated by the type III secretion toxin ExoU from Pseudomonas aeruginosa. PLoS Pathog 8:e1002637. http://dx.doi.org/10.1371/journal.ppat.1002637.
15. Barbieri JT, Sun J. 2004. Pseudomonas aeruginosa ExoS and ExoT. Rev Physiol Biochem Pharmacol 152:79-92.
16. Huber P, Bouillot S, Elsen S, Attree I. 2014. Sequential inactivation of Rho GTPases and Lim kinase by Pseudomonas aeruginosa toxins ExoS and ExoT leads to endothelial monolayer breakdown. Cell Mol Life Sci 71:1927-1941. http://dx.doi.org/10.1007/s00018-013-1451-9.
17. Ganter MT, Roux J, Su G, Lynch SV, Deutschman CS, Weiss YG, Christiaans SC, Myazawa B, Kipnis E, Wiener-Kronish JP, Howard M, Pittet JF. 2009. Role of small GTPases and alphavbeta5 integrin in Pseudomonas aeruginosa-induced increase in lung endothelial permeability. Am J Respir Cell Mol Biol 40:108-118. http://dx.doi.org/10.1165/rcmb.2007-0454OC.
18. Ochoa CD, Alexeyev M, Pastukh V, Balczon R, Stevens T. 2012. Pseudomonas aeruginosa exotoxin Y is a promiscuous cyclase that increases endothelial tau phosphorylation and permeability. J Biol Chem 287:25407-25418. http://dx.doi.org/10.1074/jbc.M111.301440.
19. Hurley MN, Camara M, Smyth AR. 2012. Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. Eur Respir J 40:1014-1023. http://dx.doi.org/10.1183/09031936.00042012.
20. Goure J, Pastor A, Faudry E, Chabert J, Dessen A, Attree I. 2004. The V antigen of Pseudomonas aeruginosa is required for assembly of the functional PopB/PopD translocation pore in host cell membranes. Infect Immun 72:4741-4750. http://dx.doi.org/10.1128/IAI.72.8.4741-4750.2004.
21. Elsen S, Huber P, Bouillot S, Coute Y, Fournier P, Dubois Y, Timsit JF, Maurin M, Attree I. 2014. A type III secretion negative clinical strain of Pseudomonas aeruginosa employs a two-partner secreted exolysin to induce hemorrhagic pneumonia. Cell Host Microbe 15:164-176. http://dx.doi.org/10.1016/j.chom.2014.01.003.
22. Cheng X, Ji Z, Tsalkova T, Mei F. 2008. Epac and PKA: a tale of two intracellular cAMP receptors. Acta Biochim Biophys Sin 40:651-662. http://dx.doi.org/10.1111/j.1745-7270.2008.00438.x.
23. Lorenowicz MJ, Fernandez-Borja M, Kooistra MR, Bos JL, Hordijk PL. 2008. PKA and Epac1 regulate endothelial integrity and migration through parallel and independent pathways. Eur J Cell Biol 87:779-792. http://dx.doi.org/10.1016/j.ejcb.2008.05.004.
24. Retta SF, Balzac F, Avolio M. 2006. Rap1: a turnabout for the crosstalk between cadherins and integrins. Eur J Cell Biol 85:283-293. http://dx.doi.org/10.1016/j.ejcb.2005.09.007.
25. Verove J, Bernarde C, Bohn YS, Boulay F, Rabiet MJ, Attree I, Cretin F. 2012. Injection of Pseudomonas aeruginosa Exo toxins into host cells can be modulated by host factors at the level of translocon assembly and/or activity. PLoS One 7:e30488. http://dx.doi.org/10.1371/journal.pone.0030488.
26. Mei FC, Qiao J, Tsygankova OM, Meinkoth JL, Quilliam LA, Cheng X. 2002. Differential signaling of cyclic AMP: opposing effects of exchange protein directly activated by cyclic AMP and cAMP-dependent protein kinase on protein kinase B activation. J Biol Chem 277:11497-11504. http://dx.doi.org/10.1074/jbc.M110856200.
27. Fraylick JE, Rucks EA, Greene DM, Vincent TS, Olson JC. 2002. Eukaryotic cell determination of ExoS ADP-ribosyltransferase substrate specificity. Biochem Biophys Res Commun 291:91-100. http://dx.doi.org/10.1006/bbrc.2002.6402.
28. Henriksson ML, Sundin C, Jansson AL, Forsberg A, Palmer RH, Hallberg B. 2002. Exoenzyme S shows selective ADP-ribosylation and GTPase-activating protein (GAP) activities towards small GTPases in vivo. Biochem J 367:617-628. http://dx.doi.org/10.1042/BJ20020714.
29. McGuffie EM, Frank DW, Vincent TS, Olson JC. 1998. Modification of Ras in eukaryotic cells by Pseudomonas aeruginosa exoenzyme S. Infect Immun 66:2607-2613.
30. Riese MJ, Wittinghofer A, Barbieri JT. 2001. ADP-ribosylation of Arg41 of Rap by ExoS inhibits the ability of Rap to interact with its guanine nucleotide exchange factor, C3G. Biochemistry 40:3289-3294. http://dx.doi.org/10.1021/bi002729q.
31. Norel X. 2007. Prostanoid receptors in the human vascular wall. Sci World J 7:1359-1374. http://dx.doi.org/10.1100/tsw.2007.184.
32. Johnson M. 1990. The pharmacology of salmeterol. Lung 168(Suppl):115-119.
33. Weishaar RE, Cain MH, Bristol JA. 1985. A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem 28:537-545. http://dx.doi.org/10.1021/jm50001a001.
34. Sato H, Frank DW. 2004. ExoU is a potent intracellular phospholipase. Mol Microbiol 53:1279-1290. http://dx.doi.org/10.1111/j.1365-2958.2004.04194.x.
35. Cullere X, Shaw SK, Andersson L, Hirahashi J, Luscinskas FW, Mayadas TN. 2005. Regulation of vascular endothelial barrier function by Epac, a cAMP-activated exchange factor for Rap GTPase. Blood 105:1950-1955. http://dx.doi.org/10.1182/blood-2004-05-1987.
36. Fukuhara S, Sakurai A, Sano H, Yamagishi A, Somekawa S, Takakura N, Saito Y, Kangawa K, Mochizuki N. 2005. Cyclic AMP potentiates vascular endothelial cadherin-mediated cell-cell contact to enhance endothelial barrier function through an Epac-Rap1 signaling pathway. Mol Cell Biol 25:136-146. http://dx.doi.org/10.1128/MCB.25.1.136-146.2005.
37. Wittchen ES, Worthylake RA, Kelly P, Casey PJ, Quilliam LA, Burridge K. 2005. Rap1 GTPase inhibits leukocyte transmigration by promoting endothelial barrier function. J Biol Chem 280:11675-11682. http://dx.doi.org/10.1074/jbc.M412595200.
38. Frische EW, Zwartkruis FJ. 2010. Rap1, a mercenary among the Ras-like GTPases. Dev Biol 340:1-9. http://dx.doi.org/10.1016/j.ydbio.2009.12.043.
39. Glading A, Han J, Stockton RA, Ginsberg MH. 2007. KRIT-1/CCM1 is a Rap1 effector that regulates endothelial cell-cell junctions. J Cell Biol 179:247-254. http://dx.doi.org/10.1083/jcb.200705175.
40. Noda K, Zhang J, Fukuhara S, Kunimoto S, Yoshimura M, Mochizuki N. 2010. Vascular endothelial-cadherin stabilizes at cell-cell junctions by anchoring to circumferential actin bundles through alpha- and betacatenins in cyclic AMP-Epac-Rap1 signal-activated endothelial cells. Mol Biol Cell 21:584-596. http://dx.doi.org/10.1091/mbc.E09-07-0580.
41. Pannekoek WJ, Post A, Bos JL. 2014. Rap1 signaling in endothelial barrier control. Cell Adhesion Migration 8:100-107. http://dx.doi.org/10.4161/cam.27352.
42. Birukova AA, Zebda N, Fu P, Poroyko V, Cokic I, Birukov KG. 2011. Association between adherens junctions and tight junctions via Rap1 promotes barrier protective effects of oxidized phospholipids. J Cell Physiol 226:2052-2062. http://dx.doi.org/10.1002/jcp.22543.
43. Bleves S, Viarre V, Salacha R, Michel GP, Filloux A, Voulhoux R. 2010. Protein secretion systems in Pseudomonas aeruginosa: a wealth of pathogenic weapons. Int J Med Microbiol 300:534-543. http://dx.doi.org/10.1016/j.ijmm.2010.08.005.
44. Toussaint B, Delic-Attree I, Vignais PM. 1993. Pseudomonas aeruginosa contains an IHF-like protein that binds to the algD promoter. Biochem Biophys Res Commun 196:416-421. http://dx.doi.org/10.1006/bbrc.1993.2265.
45. Cisz M, Lee PC, Rietsch A. 2008. ExoS controls the cell contact-mediated switch to effector secretion in Pseudomonas aeruginosa. J Bacteriol 190:2726-2738. http://dx.doi.org/10.1128/JB.01553-07.